 |
217 Diseases |  |
230 Trials |
|
230 Trials |  |
3979 News |  |
| «12...39404142434445464748495051 |
- || Endostar (recombinant human endostatin) / Simcere
New P3 trial: CBCRT01: Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer (clinicaltrials.gov) - Oct 25, 2011
P3, N=800, Recruiting, Sponsor: Xijing Hospital
- ||| cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
New P2/3 trial: Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients (clinicaltrials.gov) - Sep 12, 2011
P2/3, N=40, Completed, Sponsor: Dexa Medica Group
- | paclitaxel / Generic mfg., epirubicin / Generic mfg.
Enrollment open: Regimens Comparison for Breast Cancers of Positive Lymph Nodes (clinicaltrials.gov) - Sep 11, 2011
P3, N=1000, Recruiting, Sponsor: Chinese Academy of Medical Sciences
Not yet recruiting --> Recruiting
- ||||| Herceptin (trastuzumab) / Roche
New P2 trial: Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer (clinicaltrials.gov) - Sep 1, 2011
P2, N=100, Active, not recruiting, Sponsor: Zhimin Shao
- || paclitaxel / Generic mfg., capecitabine / Generic mfg., epirubicin / Generic mfg.
New P3 trial, Metastases: TEX trial: Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer (clinicaltrials.gov) - Aug 31, 2011
P3, N=304, Active, not recruiting, Sponsor: Thomas Hatschek
- | Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Trial completion: Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE) (clinicaltrials.gov) - Aug 28, 2011
P3, N=720, Completed, Sponsor: German Breast Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Herceptin (trastuzumab) / Roche
Trial completion: Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients (clinicaltrials.gov) - Aug 17, 2011
P2, N=30, Completed, Sponsor: Accelerated Community Oncology Research Network
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Herceptin (trastuzumab) / Roche
Enrollment change: Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer (clinicaltrials.gov) - Aug 10, 2011
P3, N=74, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=164 --> 74
- ||||||| Herceptin (trastuzumab) / Roche
Trial completion: Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer (clinicaltrials.gov) - Aug 10, 2011
P3, N=74, Completed, Sponsor: M.D. Anderson Cancer Center
N=164 --> 74 Active, not recruiting --> Completed